Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target

Compare

710 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MIRM Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Mirum

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MIRM Stock 12 Month Forecast

Average Price Target

$102.33

▲(31.63% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Mirum Pharmaceuticals in the last 3 months. The average price target is $102.33 with a high forecast of $140.00 and a low forecast of $81.00. The average price target represents a 31.63% change from the last price of $77.74.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"40":"$40","141":"$141","65.25":"$65.3","90.5":"$90.5","115.75":"$115.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":102.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$102.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":81,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$81.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[40,65.25,90.5,115.75,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.01,75.39384615384616,80.77769230769232,86.16153846153847,91.54538461538462,96.92923076923077,102.31307692307692,107.69692307692308,113.08076923076923,118.46461538461539,123.84846153846155,129.2323076923077,134.61615384615385,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.01,72.49615384615385,74.9823076923077,77.46846153846154,79.95461538461538,82.44076923076923,84.92692307692307,87.41307692307691,89.89923076923077,92.38538461538462,94.87153846153846,97.3576923076923,99.84384615384616,{"y":102.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.01,70.85538461538462,71.70076923076924,72.54615384615386,73.39153846153846,74.23692307692308,75.0823076923077,75.92769230769231,76.77307692307693,77.61846153846155,78.46384615384616,79.30923076923077,80.15461538461538,{"y":81,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":46.21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.04,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.42,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.39,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.65,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.01,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$140.00

Average Price Target$102.33

Lowest Price Target$81.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jonathan Wolleben

Citizens JMP

$95→$140

Buy

80.09%

Upside

Reiterated

12/19/25

Mirum Pharmaceuticals price target raised to $140 from $95 at CitizensMirum Pharmaceuticals price target raised to $140 from $95 at Citizens

Gavin Clark-Gartner

Evercore ISI

$94

Buy

20.92%

Upside

Reiterated

12/17/25

Evercore ISI Keeps Their Buy Rating on Mirum Pharmaceuticals (MIRM)

James Condulis

Stifel Nicolaus

$92→$98

Buy

26.06%

Upside

Reiterated

12/16/25

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM), Novan (NASDAQ: NOVN) and Argenx Se (NASDAQ: ARGX)

Mani Foroohar

Leerink Partners

$90→$100

Buy

28.63%

Upside

Reiterated

12/10/25

Mirum Pharmaceuticals price target raised to $100 from $90 at LeerinkMirum Pharmaceuticals price target raised to $100 from $90 at Leerink

Swayampakula Ramakanth

H.C. Wainwright

$81

Buy

4.19%

Upside

Reiterated

12/09/25

Strategic Acquisition Positions Mirum Pharmaceuticals for Leadership in Rare Liver Disease Market

Michael Ulz

Morgan Stanley

$81→$95

Buy

22.20%

Upside

Reiterated

12/09/25

Analysts' Top Healthcare Picks: Mirum Pharmaceuticals (MIRM), Eli Lilly & Co (LLY)

Brian Skorney

Robert W. Baird

$80→$88

Buy

13.20%

Upside

Reiterated

12/09/25

Mirum Pharmaceuticals price target raised to $88 from $80 at BairdMirum Pharmaceuticals price target raised to $88 from $80 at Baird

Joshua Schimmer

Cantor Fitzgerald

$95→$130

Buy

67.22%

Upside

Reiterated

12/08/25

Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor FitzgeraldMirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald

Joseph Thome

TD Cowen

$95

Buy

22.20%

Upside

Reiterated

11/12/25

TD Cowen Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)

Jessica Fye

J.P. Morgan

$53→$77

Buy

-0.95%

Downside

Reiterated

09/12/25

Mirum Pharmaceuticals price target raised to $77 from $53 at JPMorganMirum Pharmaceuticals price target raised to $77 from $53 at JPMorgan

David Lebowitz

Citi

$89

Buy

14.48%

Upside

Reiterated

08/18/25

Analysts Are Bullish on These Healthcare Stocks: Mirum Pharmaceuticals (MIRM), Century Therapeutics (IPSC)

Ryan Deschner

Raymond James

$77→$82

Buy

5.48%

Upside

Reiterated

08/07/25

Mirum Pharmaceuticals price target raised to $82 from $77 at Raymond JamesMirum Pharmaceuticals price target raised to $82 from $77 at Raymond James

Ed Arce

Westpark Capital

$66→$72

Buy

-7.38%

Downside

Reiterated

02/27/25

Mirum Pharmaceuticals: Strong Buy Rating Driven by Promising Financial Growth and Clinical Advancements

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jonathan Wolleben

Citizens JMP

$95→$140

Buy

80.09%

Upside

Reiterated

12/19/25

Mirum Pharmaceuticals price target raised to $140 from $95 at CitizensMirum Pharmaceuticals price target raised to $140 from $95 at Citizens

Gavin Clark-Gartner

Evercore ISI

$94

Buy

20.92%

Upside

Reiterated

12/17/25

Evercore ISI Keeps Their Buy Rating on Mirum Pharmaceuticals (MIRM)

James Condulis

Stifel Nicolaus

$92→$98

Buy

26.06%

Upside

Reiterated

12/16/25

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM), Novan (NASDAQ: NOVN) and Argenx Se (NASDAQ: ARGX)

Mani Foroohar

Leerink Partners

$90→$100

Buy

28.63%

Upside

Reiterated

12/10/25

Mirum Pharmaceuticals price target raised to $100 from $90 at LeerinkMirum Pharmaceuticals price target raised to $100 from $90 at Leerink

Swayampakula Ramakanth

H.C. Wainwright

$81

Buy

4.19%

Upside

Reiterated

12/09/25

Strategic Acquisition Positions Mirum Pharmaceuticals for Leadership in Rare Liver Disease Market

Michael Ulz

Morgan Stanley

$81→$95

Buy

22.20%

Upside

Reiterated

12/09/25

Analysts' Top Healthcare Picks: Mirum Pharmaceuticals (MIRM), Eli Lilly & Co (LLY)

Brian Skorney

Robert W. Baird

$80→$88

Buy

13.20%

Upside

Reiterated

12/09/25

Mirum Pharmaceuticals price target raised to $88 from $80 at BairdMirum Pharmaceuticals price target raised to $88 from $80 at Baird

Joshua Schimmer

Cantor Fitzgerald

$95→$130

Buy

67.22%

Upside

Reiterated

12/08/25

Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor FitzgeraldMirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald

Joseph Thome

TD Cowen

$95

Buy

22.20%

Upside

Reiterated

11/12/25

TD Cowen Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)

Jessica Fye

J.P. Morgan

$53→$77

Buy

-0.95%

Downside

Reiterated

09/12/25

Mirum Pharmaceuticals price target raised to $77 from $53 at JPMorganMirum Pharmaceuticals price target raised to $77 from $53 at JPMorgan

David Lebowitz

Citi

$89

Buy

14.48%

Upside

Reiterated

08/18/25

Analysts Are Bullish on These Healthcare Stocks: Mirum Pharmaceuticals (MIRM), Century Therapeutics (IPSC)

Ryan Deschner

Raymond James

$77→$82

Buy

5.48%

Upside

Reiterated

08/07/25

Mirum Pharmaceuticals price target raised to $82 from $77 at Raymond JamesMirum Pharmaceuticals price target raised to $82 from $77 at Raymond James

Ed Arce

Westpark Capital

$66→$72

Buy

-7.38%

Downside

Reiterated

02/27/25

Mirum Pharmaceuticals: Strong Buy Rating Driven by Promising Financial Growth and Clinical Advancements

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mirum Pharmaceuticals

1 Month

xxx

Success Rate

19/32 ratings generated profit

Average Return

+2.62%

reiterated a xxx

rating 10 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 59.38% of your transactions generating a profit, with an average return of +2.62% per trade.

3 Months

xxx

Success Rate

23/35 ratings generated profit

Average Return

+7.39%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.71% of your transactions generating a profit, with an average return of +7.39% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

18/19 ratings generated profit

Average Return

+42.71%

reiterated a buy rating 2 days ago

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 94.74% of your transactions generating a profit, with an average return of +42.71% per trade.

2 Years

xxx

Success Rate

18/18 ratings generated profit

Average Return

+104.69%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +104.69% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MIRM Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MIRM has received 20 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. MIRM average Analyst price target in the past 3 months is 102.33.

Each month's total comprises the sum of three months' worth of ratings.

MIRM Financial Forecast

MIRM Earnings Forecast

Next quarter’s earnings estimate for MIRM is -$0.06 with a range of -$0.26 to $0.06. The previous quarter’s EPS was $0.05. MIRM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MIRM has Performed in-line its overall industry.

MIRM Sales Forecast

Next quarter’s sales forecast for MIRM is $135.72M with a range of $131.00M to $138.60M. The previous quarter’s sales results were $133.01M. MIRM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MIRM has Performed in-line its overall industry.

MIRM Stock Forecast FAQ

What is MIRM’s average 12-month price target, according to analysts?

Based on analyst ratings, Mirum Pharmaceuticals’s 12-month average price target is 102.33.

What is MIRM’s upside potential, based on the analysts’ average price target?

Mirum Pharmaceuticals has 31.63% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MIRM a Buy, Sell or Hold?

Mirum Pharmaceuticals has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Mirum Pharmaceuticals’s price target?

The average price target for Mirum Pharmaceuticals is 102.33. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $140.00 ,the lowest forecast is $81.00. The average price target represents 31.63% Increase from the current price of $77.74.

What do analysts say about Mirum Pharmaceuticals?

Mirum Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of MIRM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target

MIRM Analyst Ratings

MIRM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Mirum Pharmaceuticals

MIRM Analyst Recommendation Trends

MIRM Financial Forecast

MIRM Earnings Forecast

MIRM Sales Forecast

MIRM Stock Forecast FAQ

Detailed List of Analyst Forecasts